assessment report - european medicines agency · assessment report . blitzima . international...

Download Assessment report - European Medicines Agency · Assessment report . Blitzima . International non-proprietary name: rituximab . Procedure No. EMEA/H/C/004723/0000 . Note . Assessment

If you can't read please download the document

Upload: others

Post on 17-Jun-2020

0 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

ASSESSMENT REPORT FOR MABTHERA rituximab Procedure No ... · Doc. Ref No.:EMEA/505441/2009 ASSESSMENT REPORT FOR MABTHERA ... anemia or Richter’s transformation: First interim analysis

Rituximab in Nephrology · Rituximab in Nephrology Dr F. Moeinzadeh and polymyositis 12/7/1397 4. Clinical use of rituximab in renal transplantation Induction Desensitization in antibody

CVMP assessment report for Forceris (EMEA/V/C/004329/0000)€¦ · CVMP assessment report for Forceris (EMEA/V/C/004329/0000) EMA/138662/2019 Page 5/37 Part 1 - Administrative particulars

Rituximab Biosimilar Brochure

Rituximab in nephrology

5.01.556 Rituximab: Non-oncologic and Miscellaneous UsesLupus nephritis Rituxan® (rituximab) OR Ruxience™ (rituximab-pvvr) may be considered medically necessary as first line products

WITHDRAWAL ASSESSMENT REPORT THERALOC · Doc. Ref: EMEA/67305/2009 WITHDRAWAL ASSESSMENT REPORT FOR THERALOC International Nonproprietary Name: nimotuzumab Procedure No. EMEA/H/C/931

Cetuximab and Rituximab

Rituximab and Hyaluronidase injection, for subcutaneous use · 1 Rituximab and Hyaluronidase injection, for subcutaneous use (rituximab SC) BLA 761064 R. Angelo de Claro, MD Medical

KRIBIOLISA™ Anti-Rituximab ELISA€¦ · The KRIBIOLISA™ Anti-Rituximab ELISA is used as an analytical tool for quantitative determination of Anti-Rituximab in serum, plasma and

CVMP assessment report for Vectra 3D (EMEA/V/C… · CVMP assessment report for Vectra 3D (EMEA/V/C/002555/0000) EMA/675222/2013 Page 5/32 . Active substance - permethrin . Permethrin

(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine

CP.PHAR.260 Rituximab (Rituxan), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab … · Rituximab, Rituximab-pvvr, Rituximab-abbs, Rituximab-Hyaluronidase Page 4 of

CVMP assessment report for Bravecto (EMEA/V/C/002526/0000) · CVMP assessment report for Bravecto (EMEA/V/C/002526/0000) EMA/18748/2014 Page 2/22 Introduction . The applicant Intervet

REGENERATION LYMPHOCYTAIRE B POST-RITUXIMAB DANS …

Assessment Report For (nilotinib) Procedure No.: EMEA/H/C ... · Procedure No.: EMEA/H/C/000798/II/0029 . Variation Assessment Report as adopted by the CHMP with . all information

Successful practice changing development plans: Rituximab ... · Rituximab may have unexpected/severe toxicity in children Two rituximab phase 2 trials in children ... protocol APR2010

Integrated Impact Assessment Report for Clinical ... · Integrated Impact Assessment Report for Clinical Commissioning Policies Policy Reference Number 1625 Policy Title Rituximab

CVMP assessment report for Baycox Iron (EMEA/V/C/004794/0000) › en › documents › assessment-report › ... · CVMP assessment report for Baycox Iron (EMEA/V/C/004794/0000) EMA/193625/2019

Assessment Report For MabThera (rituximab) … · recommended for patients ... two-arm study comparing rituximab maintenance with observation, ... number of immunochemotherapy cycles

Australian Public Assessment Report for Rituximab · Australian Public Assessment Report for Rituximab ... Roche Products Pty ... published as papers in peer-reviewed journals or

Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA ... · Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA 761064 . ADVISORY COMMITTEE BRIEFING MATERIALS Available

Ofatumumab For Rituximab-resistant Nephrotic Syndrome

WITHDRAWAL ASSESSMENT REPORT FOR Garenoxac in ......Doc. Ref: EMEA/CHMP/363573/2007 WITHDRAWAL ASSESSMENT REPORT FOR in Mesylate (garenoxacin) London, 1 Garenoxac EMEA/H/C/747 Day

Targeted Therapy with Rituximab in Felty’s Syndrome: A ... of Felty’s Syndrome with Rituximab The Open Rheumatology Journal, 2012, Volume 6 313 and a treatment with rituximab was

Withdrawal assessment report for Oncept Melanoma (EMEA/V/C

Uses of Rituximab in Nephrology

Australian public assessment for Rituximab · Web viewThis AusPAR describes the application by the sponsor to register an alternative, faster (2 h) infusion schedule of MabThera (rituximab)

Rituximab in Chronic Lymphocytic Leukemia

Australian Public Assessment Report for Rituximab · AusPAR Riximyo rituximab Sandoz Pty Ltd PM-2016-03153-1-4 Final 23 August 2018 Page 3 of 70 Contents Common abbreviations _____

Rituximab efficacy in other haematological malignancies

CVMP assessment report for Vectra Felis (EMEA/V/C… · CVMP assessment report for Vectra Felis (EMEA/V/C/002746) EMA/228019/2014 3/23 . The detailed description of the pharmacovigilance

Rituximab in Vasculitis - academia.cat · Rituximab in Vasculitis Pr Patrice CACOUB, MD ... Treatment of Systemic ANCA Vasculitis Summary

CVMP assessment report for Simparica Trio (EMEA/V/C/004846 ... · CVMP assessment report for Simparica Trio (EMEA/V/C/004846/0000) EMA/413747/2019 Page 4/49 Introduction The applicant

Cladribine + Rituximab in HCL : UPDATE